WALTHAM, Mass., Dec. 22 Inverness MedicalInnovations, Inc. (Amex: IMA), a leading provider of near-patient diagnostics,monitoring and health management solutions, announced today that it intends tomove the trading of its listed securities to the New York Stock Exchange(NYSE). The Company has filed its listing application with NYSE and currentlyexpects its listings on NYSE to commence on January 6, 2009. Until that timethe Company's shares will continue to trade on Alternext (formerly theAmerican Stock Exchange). The Company's Common Stock will continue to tradeunder the symbol, "IMA" and its Series B Convertible Perpetual Preferred Stockwill continue to trade under the symbol, "IMA.PR.B".
"We are proud to be able to move our listings over to the New York StockExchange and offer our shareholders the increased liquidity and visibilityavailable through this premier exchange," said Ron Zwanziger, Inverness'Chairman, Chief Executive Officer and President. "We look forward to a longand successful relationship with NYSE."
"We are pleased to welcome Inverness, a leader in medical diagnosticsproducts and health management, to our family of listed companies," saidDuncan Niederauer, NYSE Euronext CEO. "Inverness recognizes the value andbenefits of listing on the NYSE, and we look forward to serving the companyand its shareholders."
By developing new capabilities in near-patient diagnosis, monitoring andhealth management, Inverness Medical Innovations enables individuals to takecharge of improving their health and quality of life. A global leader in rapidpoint-of-care diagnostics, Inverness' products, as well as its new productdevelopment efforts, focus on infectious disease, cardiology, oncology, drugsof abuse and women's health. Inverness is headquartered in Waltham,Massachusetts.
For more information about Inverness Medical Innovations, please visit ourwebsite at http://www.invernessmedical.com.
This press release may contain forward-looking statements within themeaning of the federal securities laws, including statements regarding plannedmovement of the companies securities listings to the NYSE, the expect timingof the listing and the potential benefits of the change. These statementsreflect Inverness' current views with respect to future events and are basedon its management's current assumptions and information currently available.Actual results may differ materially due to numerous factors including,without limitation, risks associated with NYSE application and review process;and the risks and uncertainties described in Inverness' annual report on Form10-K, and other factors identified from time to time in its periodic filingswith the Securities and Exchange Commission. Inverness undertakes noobligation to update any forward-looking statements contained herein.
SOURCE Inverness Medical Innovations, Inc.